Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday. The post Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test appeared first on Investor's Business Daily.